muscle stem cells fused into multinucleated myotubes
© Spuler Lab, MDC Berlin

Technology & Licensing

Our technology offers

The Max Delbrück Center has a unique record of discovery and innovation leading to a diverse technology portfolio.

To find solutions for your business and technology needs, have a look at our technology offers on the website of our commercialization partner Ascenion. 

We also encourage you to contact us for more information about current technology development at the Max Delbrück Center and the researchers behind them.

Intellectual property & patents

The Max Delbrück Center holds patents for technologies in 86 areas (including products and applications), with a total of 571 successful patents worldwide.

About the header image
mRNA introduced the gene editor CRISPR-Cas9 into human muscle stem cells
muscle stem cells fused into multinucleated myotubes

The researchers used mRNA to introduce the gene editor CRISPR-Cas9 into human muscle stem cells. These cells fused into multinucleated myotubes following mRNA-mediated CRISPR-Cas9 gene editing. A myosin heavy chain is seen in green and the nuclei in blue.

© Spuler Lab, MDC Berlin

Further information 

Related news & events

Oscar Sánchez-Carranza und Jeanne Mbebi

Oscar Sánchez-Carranza (links) und Jeanne Mbebi (rechts) gehören zu den sieben Postdoktorand*innen, die in diesem Jahr einen Ausflug in die Industrie gemacht haben.

© Felix Petermann, Max Delbrück Center
Science

A practical test for postdocs

For some researchers, a career in industry would never be an option. Others appreciate the practical relevancy of working at a company. Postdocs at the Max Delbrück Center can find out which path is right for them through the “Academy meets Industry” program.
Wissenschaftliches Bild
© David Ausserhofer, Max Delbrück Center
Press Release No. 22

Sharpening the gene scissors together

The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases.
Simon Haas

Simon Haas

© Felix Petermann, Max Delbrück Center
Press Release No. 21

Simon Haas awarded ERC Proof of Concept Grant

Simon Haas receives a Proof-of-Concept Grant from the European Research Council in the amount of €150,000. Immunotherapies use the immune system to fight against cancer. Haas' team from the joint single-cell focus of Max Delbrück Center, BIH, and Charité is developing methods to predict the efficacy of immunotherapies.
Panel discussion

Panel discussion with (f.l.t.r.): Frauke Hein (Scienion), Simon Haas (Max Delbrück Center), Kai Uwe Bindseil (host), Maike Sander (Max Delbrück Center), Nikolaus Rajewsky (Max Delbrück Center) and Gary Kruppa (Bruker)

© Felix Petermann, Max Delbrück Center
Press Release No. 18

New center of excellence for single cell omics

On July 8, the Max Delbrück Center and Bruker will kick off a strategic partnership to build a first-of-its-kind innovation hub for systems medicine. The new center will focus on the development and application of mass spectrometry based single-cell and multi-omics technologies.